Supplementary Table 1 from Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion

Victoria M. Rimkunas,Katherine E. Crosby,Daiqiang Li,Yerong Hu,Meghan E. Kelly,Ting-Lei Gu,Jennifer S. Mack,Matthew R. Silver,Xinmin Zhou,Herbert Haack

DOI: https://doi.org/10.1158/1078-0432.22447482.v1

2023-01-01

Abstract:XLSX file, 43KB, RT-PCR Results for FFPE ROS positive tumors.

What problem does this paper attempt to address?

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Humam Kadara,Li Shen,Junya Fujimoto,Pierre Saintigny,Chi-Wan Chow,Wenhua Lang,Zuoming Chu,Melinda Garcia,Mohamed Kabbout,You-Hong Fan,Carmen Behrens,Diane A. Liu,Li Mao,J. Jack Lee,Kathryn A. Gold,Jing Wang,Kevin R. Coombes,Edward S. Kim,Waun Ki Hong,Ignacio I. Wistuba

DOI: https://doi.org/10.1158/1940-6207.22524609.v1

2023-01-01

Abstract:XLSX file - 68K, Supplementary table depicting 1165 genes significantly differentially expressed by site in the molecular field of injury
Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528425

2023-01-01

Abstract:PDF file, 64K, Non-small cell lung cancer cell lines.
Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528440.v1

2023-01-01

Abstract:PDF file, 125K, Western blot of total PARP1.
Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Inna Smalley,Zhihua Chen,Manali S. Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod A. Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J.B. Macaulay,Zeynep Eroglu,Peter Forsyth,Paulo C. Rodríguez,Yigiang Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22481007.v1

2023-01-01

Abstract:Supplemental Table 1: Flow Cytometry Antibodies
Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Yan Lü,Ming You,Zara Ghazoui,Pengyuan Liu,Peter T. Vedell,Wen Wang,Ann M. Bode,Clinton J. Grubbs,Ronald A. Lubet

DOI: https://doi.org/10.1158/1940-6207.22524285

2023-01-01

Abstract:XLSX file - 87K, Gene Expression Changes Comparing Control Rat Tumors and Rat Tumors Treated with Vorozole
Supplementary Table 2 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Yan Lu,Ming You,Zara Ghazoui,Pengyuan Liu,Peter T. Vedell,Weidong Wen,Ann M. Bode,Clinton J. Grubbs,Ronald A. Lubet

DOI: https://doi.org/10.1158/1940-6207.22524282

2023-01-01

Abstract:XLSX file - 244K, Gene Expression Changes Comparing Control Breast Cancers and Letrozole Treated Breast Cancer in Humans (GSE 5462)
Supplementary Table 5 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461759.v1

2023-01-01

Abstract:PDF file - 56KB, Correlation between FGFR fusion and expression.
Supplementary Table 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461774.v1

2023-01-01

Abstract:Clinicopathologic Characteristics in NSCLC Patients with FGFR, ALK, RET and ROS1 fusions
A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas Based on Histologic Features.

Jianya Zhou,Jing Zhao,Jing Zheng,Mei Kong,Ke Sun,Bo Wang,Xi Chen,Wei Ding,Jianying Zhou

DOI: https://doi.org/10.1371/journal.pone.0161861

IF: 3.7

2016-01-01

PLoS ONE

Abstract:AIMS:To identify the clinical and histological characteristics of ROS1-rearranged non-small-cell lung carcinomas (NSCLCs) and build a prediction model to prescreen suitable patients for molecular testing. METHODS AND RESULTS:We identified 27 cases of ROS1-rearranged lung adenocarcinomas in 1165 patients with NSCLCs confirmed by real-time PCR and FISH and performed univariate and multivariate analyses to identify predictive factors associated with ROS1 rearrangement and finally developed prediction model. Detected with ROS1 immunochemistry, 59 cases of 1165 patients had a certain degree of ROS1 expression. Among these cases, 19 cases (68%, 19/28) with 3+ and 8 cases (47%, 8/17) with 2+ staining were ROS1 rearrangement verified by real-time PCR and FISH. In the resected group, the acinar-predominant growth pattern was the most commonly observed (57%, 8/14), while in the biopsy group, solid patterns were the most frequently observed (78%, 7/13). Based on multiple logistic regression analysis, we determined that female sex, cribriform structure and the presence of psammoma body were the three most powerful indicators of ROS1 rearrangement, and we have developed a predictive model for the presence of ROS1 rearrangements in lung adenocarcinomas. CONCLUSIONS:Female, cribriform structure and presence of psammoma body were the three most powerful indicator of ROS1 rearrangement status, and predictive formula was helpful in screening ROS1-rearranged NSCLC, especially for ROS1 immunochemistry equivocal cases.
Supplementary Tables 1-5 from 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Nicolaos Palaskas,Steven M. Larson,Nikolaus Schultz,Evangelia Komisopoulou,Justin Wong,Dan Rohle,Carl Campos,Nicolas Yannuzzi,Joseph R. Osborne,Irina Linkov,Edward R. Kastenhuber,Richard Taschereau,Seema B. Plaisier,Chris Tran,Adriana Heguy,Hong Wu,Chris Sander,Michael E. Phelps,Cameron Brennan,Elisa Port,Jason T. Huse,Thomas G. Graeber,Ingo K. Mellinghoff

DOI: https://doi.org/10.1158/0008-5472.22388186

2023-01-01

Abstract:XLS file - 1.38 MB
Supplementary Data 2 from Generation of Prostate Tumor–Initiating Cells Is Associated with Elevation of Reactive Oxygen Species and IL-6/STAT3 Signaling

Yi Qu,Anne Margrete Oyan,Runhui Liu,Yaping Hua,Jigang Zhang,Randi Hovland,Mihaela Popa,Xiaojun Liu,Karl A. Brokstad,Ronald Simon,Anders Molven,Biaoyang Lin,Wei-dong Zhang,Emmet McCormack,Karl-Henning Kalland,Xi-Song Ke

DOI: https://doi.org/10.1158/0008-5472.22398897

2023-01-01

Abstract:XLS file 35K, Chromosomal aberrations of the EPT3-M1.
Supplementary Tables from CD74–NRG1 Fusions in Lung Adenocarcinoma

Lynnette Fernandez-Cuesta,Dennis Plenker,Hirotaka Osada,Ruping Sun,Roopika Menon,Frauke Leenders,Sandra Ortiz-Cuaran,Martin Peifer,Marc Bos,Juliane Daßler,Florian Malchers,Jakob Schöttle,Wenzel Vogel,Ilona Dahmen,Mirjam Koker,Roland T. Ullrich,Gavin M. Wright,Prudence A. Russell,Zoe Wainer,Benjamin Solomon,Elisabeth Brambilla,Hélène Nagy-Mignotte,Denis Moro-Sibilot,Christian G. Brambilla,Sylvie Lantuejoul,Janine Altmüller,Christian Becker,Peter Nürnberg,Johannes M. Heuckmann,Erich Stoelben,Iver Petersen,Joachim H. Clement,Jörg Sänger,Lucia A. Muscarella,Annamaria la Torre,Vito M. Fazio,Idoya Lahortiga,Timothy Perera,Souichi Ogata,Marc Parade,Dirk Brehmer,Martin Vingron,Lukas C. Heukamp,Reinhard Buettner,Thomas Zander,Jürgen Wolf,Sven Perner,Sascha Ansén,Stefan A. Haas,Yasushi Yatabe,Roman K. Thomas

DOI: https://doi.org/10.1158/2159-8290.22530114.v1

2023-01-01

Abstract:XLSX file 75K, This is an excel file containing 9 sheets, one for each of the 9 supplementary tables (S1 to S9) mentioned in the main text
EP1.14-45 ROS1-ADGRG6: A Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib

X. Li,C. Xu,S. Xu,W. Wang,J. Ye,Y. Zhu,T. Ge,M. Fang,T. Lv,Y. Song

DOI: https://doi.org/10.1016/j.jtho.2019.08.2330

IF: 20.121

2019-01-01

Journal of Thoracic Oncology

Abstract:ROS1 rearrangements are validated driver genes in non-small cell lung cancer (NSCLC) and have been identified in a small subset (1%-2%) of patients with NSCLC. To date, 18 different fusion genes of ROS1 in NSCLC have been identified. The ALK inhibitor, crizotinib, exhibits therapeutic efficacy against ROS1-rearranged NSCLC. In addition to immunohistochemistry, real-time PCR, and fluorescence in situ hybridization, next-generation sequencing (NGS) technology represents a novel tool for ROS1 detection that covers a wide range of fusion genes. A 55-year-old female with stage IV was detected with a novel ROS1 fusion afther treated with gefitinib due to detection of an EGFR mutation (L858R). Histological examination was consistent with lung adenocarcinoma. A NGS assay showed that the tumor had a novel ROS1-ADGRG6 rearrangement generated by the fusion of exons of 1-33 of ROS1 on chr6: q22.1 to exons of 2-26 of ADGRG6 on chr6: q24.2. The predicted ROS1-ADGRG6 protein product contained 3075 amino acids comprising the N-terminal amino acids 1-1853 of ROS1 and C-terminal amino acid 1-1222 of ADGRG6. The patient had a favorable tumor response to crizotinib. ROS1-ADGRG6 is a novel ROS1 fusion gene in NSCLC detected by NGS and should be considered in ROS1 detection assays.
Supplementary Table 5 and 6 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Rui Wang,Lei Wang,Yuan Li,Haichuan Hu,Lei Shen,Xuxia Shen,Yunjian Pan,Ting Ye,Yang Zhang,Xiaoyang Luo,Yiliang Zhang,Bin Pan,Bin Li,Hang Li,Jie Zhang,William Pao,Hongbin Ji,Yihua Sun,Haiquan Chen

DOI: https://doi.org/10.1158/1078-0432.22461762.v1

2023-01-01

Abstract:Table 5:Correlation between FGFR fusion and expression Table 6: Clinicopathologic Characteristics of 734 Patients with NSCLC in Survival analysis
Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Genee Y. Lee,Peter M. Haverty,Li Li,Noelyn M. Kljavin,Richard Bourgon,James Lee,Howard Stern,Zora Modrusan,Somasekar Seshagiri,Zemin Zhang,David Davis,David Stokoe,Jeffrey Settleman,Frederic J. de Sauvage,Richard M. Neve

DOI: https://doi.org/10.1158/0008-5472.22399124

2023-01-01

Abstract:XLSX file - 37K, Supplementary materials and methods (cell lines, STR profiles, primers, antibodies, molecular reagents).
Clinicopathologic Characteristics of Patients with ROS1 Fusion Gene in Non-Small Cell Lung Cancer: a Meta-Analysis.

Qingqing Zhu,Ping Zhan,Xinlin Zhang,Tangfeng Lv,Yong Song

DOI: https://doi.org/10.3978/j.issn.2218-6751.2015.05.01

2015-01-01

Abstract:BACKGROUND:The receptor tyrosine kinase ROS1 is a driver gene in the non-small cell lung cancer (NSCLC) with promising target treatment potential. The clinical features of NSCLC patients harboring ROS1 fusion gene were not fully understood due to small-to-modest sample sizes of these association studies.METHODS:We systematically searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from their inception to March 31, 2015. We analyzed the association between ROS1 fusion genes and four common clinical variables, i.e., gender, smoking status, pathological type and clinical stage.RESULTS:Eighteen studies consisting of 9,898 NSCLC patients were included in this meta-analysis. Pooled results showed that significantly higher rate of ROS1 fusion gene was detected in female NSCLC patients (OR =1.54, 95% CI: 1.02-2.34, P=0.042), patients without a smoking history (OR =3.27, 95% CI: 1.44-7.45, P=0.005), patients with adenocarcinomas NSCLC (OR =10.24, 95% CI: 5.13-20.40, P<0.001), and patients with an advanced clinical stages III-IV (OR =2.57, 95% CI: 1.78-3.71, P<0.001). The pooled prevalence of ROS1 fusion gene was 2.4% (95% CI: 1.8-3.1%) in adenocarcinoma and a significantly lower (0.2%) in non-adenocarcinoma tumors.CONCLUSIONS:ROS1 rearrangement was more prevalent in female patients, patients without a smoking history, patients with adenocarcinoma, and patients on more advanced stages (stages III to IV).
Analysis of RET Rearrangement in Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion

W-X. Wang,C. Xu,W. Zhuang,Y. Tian,J. Xu,M. Fang,Y. Chen,G. Chen,T. Lv,Y. Song

DOI: https://doi.org/10.1016/s1556-0864(18)30311-3

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:Background: ROS1 rearrangement in non-small cell lung cancer (NSCLC) patients has recently been identified as a driver gene event and patients benefi from crizotinib treatment. The aim of this study was to investigate the clinical value of ROS1 rearrangement non-small cell lung cancer (NSCLC) cell blocks from pleural effusion. Methods: Two hundred and fifteen cases of ROS1 rearrangement non-small cell lung cancer (NSCLC) blocks cell from pleural effusion, and 404 cases of tissues were analysed by the reverse transcription polymerase chain reaction (RT-PCR) method. The consistency of ROS1 rearrangement was examined in 74 cases of patients with tissues and cell blocks. Results: ROS1 rearrangement was found in 7 of 215 cell blocks (positive detection rate of 3.26%). ROS1 rearrangement was detected in 8 of 404 tissue blocks (positive detection rate of 1.98%). There were 71 cases of the 74 (95.95%) cases that had the same consistency as tissue block. ROS1 rearrangement was detected in 2 of 74 (2.70%) cell blocks, and 5 of 74 (6.76%) tissue blocks. Conclusions: The rate of ROS1 rearrangement in cell blocks of NSCLC is higher than in matched tissue blocks. The patients with malignant pleural effusion are likely to tend to ROS1 rearrangement. Legal entity responsible for the study: Wenxian Wang Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest.

Supplementary Table 1 from Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 2 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 5 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas Based on Histologic Features.

Supplementary Tables 1-5 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Data 2 from Generation of Prostate Tumor–Initiating Cells Is Associated with Elevation of Reactive Oxygen Species and IL-6/STAT3 Signaling

Supplementary Tables from CD74–NRG1 Fusions in Lung Adenocarcinoma

EP1.14-45 ROS1-ADGRG6: A Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib

Supplementary Table 5 and 6 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Clinicopathologic Characteristics of Patients with ROS1 Fusion Gene in Non-Small Cell Lung Cancer: a Meta-Analysis.

Analysis of RET Rearrangement in Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion

Supplementary Table 1 from Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER&lt;sup&gt;+&lt;/sup&gt; Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 2 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER&lt;sup&gt;+&lt;/sup&gt; Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 5 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas Based on Histologic Features.

Supplementary Tables 1-5 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Data 2 from Generation of Prostate Tumor–Initiating Cells Is Associated with Elevation of Reactive Oxygen Species and IL-6/STAT3 Signaling

Supplementary Tables from CD74–NRG1 Fusions in Lung Adenocarcinoma

EP1.14-45 ROS1-ADGRG6: A Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib

Supplementary Table 5 and 6 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Clinicopathologic Characteristics of Patients with ROS1 Fusion Gene in Non-Small Cell Lung Cancer: a Meta-Analysis.

Analysis of RET Rearrangement in Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion

Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 2 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes